BACKGROUND: Q fever remains an important occupational zoonosis in rural Australia. Although Q fever vaccine is recommended in high-risk occupational groups, its availability has been limited in recent years. METHOD: A literature review of the efficacy of the human Q fever vaccine registered in Australia was conducted. RESULTS: Seven relevant vaccine efficacy studies were identified but no large double-blind, randomised, placebo-controlled studies have been conducted. Vaccine efficacy has ranged from 83-100% but limitations of study designs hamper a precise estimate of vaccine efficacy. CONCLUSION: Despite the shortcomings of efficacy studies, the Q fever vaccine available in Australia has considerable protective benefit in established high-risk environments, particularly of an occupational nature.
BACKGROUND: Q fever remains an important occupational zoonosis in rural Australia. Although Q fever vaccine is recommended in high-risk occupational groups, its availability has been limited in recent years. METHOD: A literature review of the efficacy of the human Q fever vaccine registered in Australia was conducted. RESULTS: Seven relevant vaccine efficacy studies were identified but no large double-blind, randomised, placebo-controlled studies have been conducted. Vaccine efficacy has ranged from 83-100% but limitations of study designs hamper a precise estimate of vaccine efficacy. CONCLUSION: Despite the shortcomings of efficacy studies, the Q fever vaccine available in Australia has considerable protective benefit in established high-risk environments, particularly of an occupational nature.
Authors: Anja Scholzen; Guilhem Richard; Leonard Moise; Laurie A Baeten; Patrick M Reeves; William D Martin; Timothy A Brauns; Christine M Boyle; Susan Raju Paul; Richard Bucala; Richard A Bowen; Anja Garritsen; Anne S De Groot; Ann E Sluder; Mark C Poznansky Journal: Front Immunol Date: 2019-02-15 Impact factor: 7.561
Authors: Anja Scholzen; Margot de Vries; Hans-Peter Duerr; Hendrik-Jan Roest; Ann E Sluder; Mark C Poznansky; Milou L C E Kouwijzer; Anja Garritsen Journal: Front Immunol Date: 2021-07-28 Impact factor: 7.561
Authors: K A Bond; G Vincent; C R Wilks; L Franklin; B Sutton; J Stenos; R Cowan; K Lim; E Athan; O Harris; L Macfarlane-Berry; Y Segal; S M Firestone Journal: Epidemiol Infect Date: 2015-10-23 Impact factor: 2.451
Authors: P M Reeves; S Raju Paul; L Baeten; S E Korek; Y Yi; J Hess; D Sobell; A Scholzen; A Garritsen; A S De Groot; L Moise; T Brauns; R Bowen; A E Sluder; M C Poznansky Journal: Sci Rep Date: 2020-08-07 Impact factor: 4.379